<DOC>
	<DOCNO>NCT00380250</DOCNO>
	<brief_summary>The primary purpose study evaluate efficacy safety administration lubiprostone patient irritable bowel syndrome constipation .</brief_summary>
	<brief_title>Efficacy Safety Lubiprostone Patients With Irritable Bowel Syndrome With Constipation</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<mesh_term>Lubiprostone</mesh_term>
	<criteria>18 year age older Stable fiber therapy Normal colonoscopy/sigmoidoscopy Able refrain use medication know treat associate constipation symptom Experiences abdominal discomfort/pain associate bowel movement Reports decrease bowel movement frequency and/or symptom associate constipation Diarrheapredominant alternating ( diarrhea constipation cycling ) irritable bowel syndrome ( IBS ) , constipation associate IBS Open gastrointestinal abdominal surgery prior IBS onset Organic bowel disorder , mechanical bowel obstruction , pseudoobstruction , unexplained weight loss rectal bleed Uncontrolled cardiovascular , liver lung disease , neurologic psychiatric disorder , systemic disease , abnormal laboratory test per investigator discretion If female , currently pregnant nursing , plan become pregnant nurse clinical study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>